Related Experiment Video
Updated: Apr 26, 2026
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
Published on: October 2, 2015
Intratumorally implanted mesenchymal stromal cells potentiate peripheral immunotherapy against malignant rat gliomas
Salina Ströjby1, Sofia Eberstål1, Andreas Svensson1
1Bengzon Group, Lund Stem Cell Center, Division of Neurosurgery, Department of Clinical Sciences, Lund University, BMC B10, SE-221 84 Lund, Sweden.
Abstract:
Bone marrow-derived mesenchymal stromal cells (MSCs) target glioma extensions and micro-satellites efficiently when implanted intratumorally. Here, we report that intratumoral implantation of MSCs and peripheral immunotherapy with interferon-gamma (IFNγ) producing tumor cells improve the survival of glioma-bearing rats (54% cure rate) compared to MSC alone (0% cure rate) or immunotherapy alone (21% cure rate) by enforcing an intratumoral CD8(+) T cell response. Further analysis revealed that the MSCs up-regulate MHC classes I and II in response to IFNγ treatment in vitro and secrete low amounts of immunosuppressive molecules prostaglandin E2 and interleukin-10.
